Pharmaceutical combination comprising the PI3K inhibitor alpelisib and the B-RAF inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
AssigneeNovartis AG
InventorsGiordano Caponigro, Thomas Horn-Spirohn, Joseph Lehar
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a pharmaceutical combination comprising (a) alpha-isoform specific PI3K inhibitor and (b) a B-RAF inhibitor; combined preparations and pharmaceutical compositions thereof; the uses of such combination in the treatment or prevention of cancer; and methods of treating or preventing cancer in a subject comprising administering a therapeutically effective amount of such combination.
Claims3
A method for treating a colorectal cancer in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical combination comprising:
- (a) a compound having the structure of Formula (I)
- or a pharmaceutically acceptable salt thereof, and
- (b) a compound having the structure of Formula (II)
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.